Doctoral School of Clinical Neuroscience, Medical School, University of Pécs, Pécs, Hungary.
Doctoral School of Clinical Neuroscience, Medical School, University of Pécs, Pécs, Hungary; Department of Neurology, Medical School, University of Pécs, Pécs, Hungary.
Parkinsonism Relat Disord. 2019 May;62:117-121. doi: 10.1016/j.parkreldis.2019.01.005. Epub 2019 Jan 4.
Although trimetazidine may induce parkinsonian symptoms in some patients, no systematic characterization has been reported on parkinsonism occurring during trimetazidine treatment since the first case reports.
To systematically investigate parkinsonism occurring during trimetazidine use.
Thirty-three consecutive patients on trimetazidine treatment with previously unrecognized parkinsonian symptoms were enrolled. Detailed neurological and neuropsychological examinations were performed at baseline and 1 and 12 months after trimetazidine withdrawal. In cases with persisting parkinsonian symptoms and suspected de novo Parkinson's disease, antiparkinsonian treatment was initiated. Twenty of the 33 patients underwent DaTSCAN imaging.
After trimetazidine withdrawal, parkinsonism was completely resolved in 11 cases. The comparison of baseline data of patients with reversible and persisting parkinsonism showed that trimetazidine-induced reversible parkinsonism was mainly characterized by akinesia, rigidity, postural instability and gait disturbances (PIGD; PIGD scores: 5.3 ± 3.8 vs. 2.0 ± 1.6 points, p = 0.006) rather than tremors (tremor scores: 1.5 ± 2.2 vs. 7.7 ± 4.6 points, p = 0.000). Trimetazidine-induced reversible parkinsonism was also more symmetrical (asymmetry index: 3.1 ± 3.6 vs. 40.1 ± 22.2, p = 0.000) and milder in severity (MDS-UPDRS Part III. scores: 10.5 ± 19. vs. 30.5 ± 11.3, p = 0.040) than nonreversible parkinsonism. DaTSCAN images were normal in all trimetazidine-induced reversible parkinsonism patients, while these images were abnormal in every patient with nonreversible parkinsonism. In cases of nonreversible parkinsonism, preexisting, incipient Parkinson's disease was suspected by clinical appearance and a good response to antiparkinsonian medication.
Mild and symmetrical appearance of parkinsonism with normal DaTSCAN results can indicate drug-induced parkinsonism. Trimetazidine discontinuation generally results in permanent remission in such cases.
尽管曲美他嗪可能会在某些患者中引起帕金森症状,但自首例病例报告以来,尚未对曲美他嗪治疗期间发生的帕金森病进行系统描述。
系统研究曲美他嗪治疗期间发生的帕金森病。
纳入 33 例连续接受曲美他嗪治疗且以前未发现帕金森症状的患者。在停用曲美他嗪后 1 个月和 12 个月进行详细的神经和神经心理学检查。对于持续存在帕金森症状且疑似新发帕金森病的患者,开始使用抗帕金森药物进行治疗。33 例患者中有 20 例行 DaTSCAN 成像。
停用曲美他嗪后,11 例帕金森病完全缓解。可逆性和持续性帕金森病患者的基线数据比较显示,曲美他嗪诱导的可逆性帕金森病主要表现为运动迟缓、僵硬、姿势不稳和步态障碍(PIGD;PIGD 评分:5.3±3.8 分与 2.0±1.6 分,p=0.006),而不是震颤(震颤评分:1.5±2.2 分与 7.7±4.6 分,p=0.000)。曲美他嗪诱导的可逆性帕金森病也更对称(不对称指数:3.1±3.6 分与 40.1±22.2 分,p=0.000),且严重程度较轻(MDS-UPDRS 第三部分评分:10.5±19. 分与 30.5±11.3 分,p=0.040)。所有曲美他嗪诱导的可逆性帕金森病患者的 DaTSCAN 图像均正常,而非可逆性帕金森病患者的 DaTSCAN 图像均异常。在非可逆性帕金森病患者中,根据临床表现和抗帕金森药物治疗的良好反应,怀疑存在先前存在的、初期的帕金森病。
帕金森病的轻度、对称表现和正常的 DaTSCAN 结果可提示药物引起的帕金森病。停用曲美他嗪通常会导致此类病例的永久性缓解。